Dr Sands, from the Icahn School of Medicine at Mt Sinai in New York, discusses the results from the QUASAR study of guselkumab in ulcerative colitis, in which nonresponding patients received subcutaneous drug over an additional 12 weeks to...
Dr Sands, from the Icahn School of Medicine at Mt Sinai in New York, discusses the results from the QUASAR study of guselkumab in ulcerative colitis, in which nonresponding patients received subcutaneous drug over an additional 12 weeks to...
Dr Sands, from the Icahn School...